Skip to main content

Advertisement

SpringerLink
Log in

Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers

  • Review
  • Published:
Pathology & Oncology Research

Abstract

Gastric cancer is one of the most common malignancy worldwide. The various genetic and epigenetic events have been found to be associated with its carcinogenesis. The epigenetic is a heritable and transient/reversible change in the gene expression that is not accompanied by modification in the DNA sequence. This event is characterized by the alteration in the promoter CpG island of the gene or histone modification. These events are associated with silencing of critical tumor suppressor gene and activation of oncogenes leading to carcinogenesis. The DNA methylation is a chemical change in the DNA sequence that most commonly occurs at cytosine moiety of CpG dinucleotide and histone, primarily on N- terminal tail that ultimately effect the interaction of DNA with chromatin modifying protein.

Hypermethylation of tumor suppressor genes and global hypomethylation of oncogenes are widely studied epigenetic modifications. There are large number of publish reports regarding epigenetic events involving gastric cancer. These changes are potentially useful in identifying markers for early diagnosis and management of this lethal malignancy. Also, role of specific miRNAs and long non coding RNAs in regulation of gene expression is gaining interest and is a matter of further investigation. In this review, we aimed to summarize major epigenetic events (DNA methylation) in gastric cancer along with alteration in miRNAs and long non coding RNAs which plays an important role in pathology of this poorly understood malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ushijima T, Sasako M (2004) Focus on gastric cancer. Cancer Cell 5(2):121–125

    Article  PubMed  CAS  Google Scholar 

  2. Tahara E (2004) Genetic pathways of two types of gastric cancer. IARC Sci Publ 157:327–349

    Google Scholar 

  3. Smith MG, Hold GL, Tahara E, El-Omar EM (2006) Cellular and molecular aspects of gastric cancer. World J Gastroenterol 12(19):2979–2990

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY (1999) Frequent somatic mutations of the beta-catenin gene in intestinal type gastric cancer. Cancer Res 59(17):4257–4260

    PubMed  CAS  Google Scholar 

  5. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF (2002) Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8(6):1761–1766

    PubMed  CAS  Google Scholar 

  6. Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Sakata K, Kashiwaba M, Satodate R (1995) The sequential accumulation of genetic alterations characteristic of the colorectal adenoma carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol 176(3):249–258

    Article  PubMed  CAS  Google Scholar 

  7. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Höfler H (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54(14):3845–3852

    PubMed  CAS  Google Scholar 

  8. Li QL, Ito K, Sakakura C, Fukamachi H, Ki I, Chi XZ et al (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109(1):113–124

    Article  PubMed  CAS  Google Scholar 

  9. Hirst M, Marra MA (2009) Epigenetics and human disease. Int J of Biochem Cell Bio 41(1):136–146

    Article  CAS  Google Scholar 

  10. Panani AD (2008) Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Letter 266(2):99–115

    Article  CAS  Google Scholar 

  11. Mulero-Navarro S, Esteller M (2008) Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 68(1):1–11

    Article  PubMed  Google Scholar 

  12. Khan FA, Shukla AN (2006) Pathogenesis and treatment of gastric carcinoma: “an up-date with brief review”. J Cancer Res Ther 2(4):196–199

    Article  PubMed  CAS  Google Scholar 

  13. Nitti D, Mocellin S, Marchet A, Pilati P, Lise M (2008) Recent advances in conventional and molecular prognostic factors for gastric carcinoma. Surg Oncol Clin N Am 17(3):467–483

    Article  PubMed  Google Scholar 

  14. Fan CY (2004) Epigenetic alterations in head and neck cancer: prevalence, clinical significance, and implications. Curr Oncol Rep 6(2):152–161

    Article  PubMed  Google Scholar 

  15. Tischoff I, Wittekind C, Tannapfel A (2006) Role of epigenetic alterations in cholangiocarcinoma. J Hepato-Biliary-Pancreat Surg 13(4):274–279

    Article  Google Scholar 

  16. Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6(8):597–610

    Article  PubMed  CAS  Google Scholar 

  17. Bird AP (1986) CpG-rich islands and the function of DNA methylation. Nature 321(6067):209–213

    Article  PubMed  CAS  Google Scholar 

  18. Nakajima T, Enomoto S, Ushijima T (2008) DNA methylation: a marker for carcinogen exposure and cancer risk. Environ Health Prev Med 13(1):8–15

    Article  PubMed  CAS  Google Scholar 

  19. Chen CZ (2005) Micro-RNAs as oncogenes and tumour suppressors. N Engl J Med 353(17):1768–1771

    Article  PubMed  CAS  Google Scholar 

  20. Calin GA, Croce CM (2006) Micro-RNA signatures in human cancers. Nat Rev Cancer 6(11):857–866

    Article  PubMed  CAS  Google Scholar 

  21. Hinshelwood RA, Clark SJ (2008) Breast cancer epigenetics: normal human mammary epithelial cells as a model system. J Mol Med 86(12):1315–1328

    Article  PubMed  Google Scholar 

  22. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415–428

    Article  PubMed  CAS  Google Scholar 

  23. Karpf AR, Jones DA (2002) Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21(35):5450–5461

    Article  CAS  Google Scholar 

  24. Lund AH, van Lohuizen M (2004) Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 16(3):239–246

    Article  PubMed  CAS  Google Scholar 

  25. Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6(11):846–856

    Article  PubMed  CAS  Google Scholar 

  26. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT (2005) Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 11(2 Pt 1):656–663

    PubMed  CAS  Google Scholar 

  27. Song SH, Jong HS, Choi HH, Kang SH, Ryu MH, Kim NK, Kim WH, Bang YJ (2000) Methylation of specific CpG sites in the promoter region could significantly down-regulate p16 (INK4a) expression in gastric adenocarcinoma. Int J Cancer 87(2):236–240

    Article  PubMed  CAS  Google Scholar 

  28. Guimarães AC, Lima EM, Khayat AS, Girão Faria MH, Barem Rabenhorst SH, Pitombeira MV, Assumpção PP, de Oliveira Bahia M, Lima de Lima PD, de Arruda Cardoso Smith M, Burbano RR (2007) Interrelationships among chromosome aneuploidy, promoter hypermethylation, and protein expression of the CDKN2A gene in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet Cytogenet 179(1):45–51

    Article  PubMed  CAS  Google Scholar 

  29. Lee JH, Park SJ, Abraham SC, Seo JS, Nam JH, Choi C, Juhng SW, Rashid A, Hamilton SR, Wu TT (2004) Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 23(26):4646–4654

    Article  PubMed  CAS  Google Scholar 

  30. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ (1999) Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59(5):1090–1095

    PubMed  CAS  Google Scholar 

  31. Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC (1999) hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 59(1):159–164

    PubMed  CAS  Google Scholar 

  32. Jung HY, Jung KC, Shim YH, Ro JY, Kang GH (2001) Methylation of the hMLH1 promoter in multiple gastric carcinomas with microsatellite instability. Pathol Int 51(6):445–451

    Article  PubMed  CAS  Google Scholar 

  33. Oue N, Shigeishi H, Kuniyasu H, Yokozaki H, Kuraoka K, Ito R, Yasui W (2001) Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer 93(6):805–809

    Article  PubMed  CAS  Google Scholar 

  34. Zazula M, Ferreira AM, Czopek JP, Kolodziejczyk P, Sinczak-Kuta A, Klimkowska A, Wojcik P, Okon K, Bialas M, Kulig J, Stachura J (2006) CDH1 gene promoter hypermethylation in gastric cancer: relationship to Goseki grading, microsatellite instability status, and EBV invasion. Diagn Mol Pathol 15(1):24–29

    Article  PubMed  CAS  Google Scholar 

  35. Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, Silva R, Muretto P, Guilford P, Testa E, Mari D, Magnani M, Cascinu S (2004) Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res 10(8):2784–2789

    Article  PubMed  CAS  Google Scholar 

  36. Liu WT, Jiao HL, Yang YL, Wang D, Zhang WM (2007) Correlation of E-cadherin hypermethylation to tumorigenesis and development of gastric cancer. Ai Zheng 26(11):1199–1203

    PubMed  CAS  Google Scholar 

  37. Terrés AM, Pajares JM, O'Toole D, Ahern S, Kelleher D (1998) Helicobacter pylori infection is associated with downregulation of E-cadherin, a molecule involved in epithelial cell adhesion and proliferation control. J Clin Pathol 51(5):410–412

    Article  PubMed  PubMed Central  Google Scholar 

  38. Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH, Hui WM, Rashid A, Kwong YL (2003) Promoter methylation of E-cadherin gene in gastric mucosa associated with helicobacter pylori infection and in gastric cancer. Gut 52(4):502–506

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Chan AO (2006) E-cadherin in gastric cancer. World J Gastroenterol 12(2):199–203

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Chan AW, Chan MW, Lee TL, Ng EK, Leung WK, Lau JY, Tong JH, Chan FK, To KF (2005) Promoter hypermethylation of death associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 13(5):937–941

    PubMed  CAS  Google Scholar 

  41. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG (2001) Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 61(19):7034–7038

    PubMed  CAS  Google Scholar 

  42. Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E, Lianidou ES, Kakolyris S (2015) Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutat Res 778:46–51

    Article  PubMed  CAS  Google Scholar 

  43. Dote H, Toyooka S, Tsukuda K, Yano M, Ota T, Murakami M, Naito M, Toyota M, Gazdar AF, Shimizu N (2005) Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer 92(6):1117–1125

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Qu Y, Dang S, Hou P (2013) Gene methylation in gastric cancer. Clin Chim Acta 424:53–65. https://doi.org/10.1016/j.cca.2013.05.002

    Article  PubMed  CAS  Google Scholar 

  45. Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, Kim HR, Chi SG (2003) Hypermethylation of XIAP associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 63(21):7068–7075

    PubMed  CAS  Google Scholar 

  46. Jee CD, Lee HS, Bae SI, Yang HK, Lee YM, Rho MS, Kim WH (2005) Loss of caspase-1 gene expression in human gastric carcinomas and cell lines. Int J Oncol 26(5):1265–1271

    PubMed  CAS  Google Scholar 

  47. Jung Y, Park J, Bang YJ, Kim TY (2008) Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Lab Investig 88(2):153–160

    Article  PubMed  CAS  Google Scholar 

  48. Lee JH, Byun DS, Lee MG, Ryu BK, Kang MJ, Chae KS, Lee KY, Kim HJ, Park H, Chi SG (2008) Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses. Int J Cancer 122(7):1573–1584

    Article  PubMed  CAS  Google Scholar 

  49. Cheng YY, Yu J, Wong YP, Man EP, To KF, Jin VX, Li J, Tao Q, Sung JJ, Chan FK, Leung WK (2007) Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br J Cancer 97(7):895–901

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Sato H, Suzuki H, Toyota M, Nojima M, Maruyama R, Sasaki S, Takagi H, Sogabe Y, Sasaki Y, Idogawa M, Sonoda T, Mori M, Imai K, Tokino T, Shinomura Y (2007) Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumours. Carcinogenesis 28(12):2459–2466

    Article  PubMed  CAS  Google Scholar 

  51. Nojima M, Suzuki H, Toyota M, Watanabe Y, Maruyama R, Sasaki S, Sasaki Y, Mita H, Nishikawa N, Yamaguchi K, Hirata K, Itoh F, Tokino T, Mori M, Imai K, Shinomura Y (2007) Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 26(32):4699–4713

    Article  PubMed  CAS  Google Scholar 

  52. Ebert MP, Yu J, Hoffmann J, Rocco A, Röcken C, Kahmann S, Müller O, Korc M, Sung JJ, Malfertheiner P (2003) Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol 21(9):1708–1714

    Article  PubMed  CAS  Google Scholar 

  53. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK, Sung JJ (2009) Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136(2):640–651

    Article  PubMed  CAS  Google Scholar 

  54. Takada H, Imoto I, Tsuda H, Nakanishi Y, Sakakura C, Mitsufuji S, Hirohashi S, Inazawa J (2006) Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. Oncogene 25(49):6554–6562

    Article  PubMed  CAS  Google Scholar 

  55. Choi MC, Jong HS, Kim TY, Song SH, Lee DS, Lee JW, Kim TY, Kim NK, Bang YJ (2004) ACAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene 23(42):7095–7103

    Article  PubMed  CAS  Google Scholar 

  56. Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K, Chayama K, Yasui W (2004) Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int J Cancer 110(2):212–218

    Article  PubMed  CAS  Google Scholar 

  57. Yamamichi N, Inada K, Ichinose M, Yamamichi-Nishina M, Mizutani T, Watanabe H, Shiogama K, Fujishiro M, Okazaki T, Yahagi N, Haraguchi T, Fujita S, Tsutsumi Y, Omata M, Iba H (2007) Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res 67(22):10727–10735

    Article  PubMed  CAS  Google Scholar 

  58. Hamai Y, Oue N, Mitani Y, Nakayama H, Ito R, Matsusaki K, Yoshida K, Toge T, Yasui W (2003) DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma. Cancer Sci 94(8):692–698

    Article  PubMed  CAS  Google Scholar 

  59. Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, Kang GH (2004) Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Investig 84(4):479–484

    Article  PubMed  CAS  Google Scholar 

  60. Hayashi K, Yokozaki H, Goodison S, Oue N, Suzuki T, Lotan R, Yasui W, Tahara E (2001) Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation 68(1):13–21

    Article  PubMed  CAS  Google Scholar 

  61. Oue N, Matsumura S, Nakayama H, Kitadai Y, Taniyama K, Matsusaki K, Yasui W (2003) Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma. Oncology 64(4):423–439

    Article  PubMed  CAS  Google Scholar 

  62. Kim TY, Jong HS, Song SH, dimtchev A, Jeong SJ, Lee JW, Kim TY, Kim NK, Jung M, Bang YJ (2003) Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 22(25):3943–3951

    Article  PubMed  CAS  Google Scholar 

  63. de Maat MF, van de Velde CJ, Umetani N, de Heer P, Putter H, van Hoesel AQ, Meijer GA, van Grieken NC, Kuppen PJ, Bilchik AJ, Tollenaar RA, Hoon DS (2007) Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol 25(31):4887–4894

    Article  PubMed  CAS  Google Scholar 

  64. Poplawski T, tomaszewska K, Galicki M, Morawiec Z, Blasiak J (2008) Promoter methylation of cancer related genes in gastric carcinoma. Exp Oncol 30(2):112–116

    PubMed  CAS  Google Scholar 

  65. Kang GH, Lee S, Kim JS, Jung HY (2003) Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Investig 83(4):519–526

    Article  PubMed  CAS  Google Scholar 

  66. Oue N, Motoshita J, Yokozaki H, Hayashi K, Tahara E, Taniyama K, Matsusaki K, Yasui W (2002) Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol 198(1):55–59

    Article  PubMed  CAS  Google Scholar 

  67. Sepulveda JL, Gutierrez-Pajares JL, Luna A, Yao Y, Tobias JW, Thomas S, Woo Y, Giorgi F, Komissarova EV, Califano A, Wang TC, Sepulveda AR (2016) High-definition CpG methylation of novel genes in gastric carcinogenesis identified by next-generation sequencing. Mod Pathol 29(2):182–193

    Article  PubMed  CAS  Google Scholar 

  68. Honda T, Tamura G, Waki T, Kawata S, Terashima M, Nishizuka S, Motoyama T (2004) Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer 90(4):838–843

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  69. Yanagawa N, Tamura G, Honda T, Endoh M, Nishizuka S, Motoyama T (2004) Demethylation of the synuclein gamma gene CpG island in primary gastric cancers and gastric cancer cell lines. Clin Cancer Res 10(7):2447–2451

    Article  PubMed  CAS  Google Scholar 

  70. Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpcao PP, Bello MJ, Rey JA, Smith MA, Casartelli C (2008) Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res 41(6):539–543

    Article  PubMed  CAS  Google Scholar 

  71. Heard E, Rougeulle C, Arnaud D, Avner P, Allis CD, Spector DL (2001) Methylation of histone H3 at Lys-9 is an early mark on the X chromosome during X inactivation. Cell 107(6):727–738

    Article  PubMed  CAS  Google Scholar 

  72. Mermoud JE, Popova B, Peters AH, Jenuwein T, Brockdorff N (2002) Histone H3 lysine 9 methylation occurs rapidly at the onset of random X chromosome inactivation. Curr Biol 12(3):247–251

    Article  PubMed  CAS  Google Scholar 

  73. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA (2002) Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 62(22):6456–6461

    PubMed  CAS  Google Scholar 

  74. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D, Jenuwein T (2004) A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 18(11):1251–1262

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ (2008) The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 15(7):1968–1976

    Article  PubMed  Google Scholar 

  76. Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumour suppressor gene silencing in colorectal cancer. Mol Cell Biol 23(1):206–215

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Watanabe Y, Toyota M, Kondo Y, Suzuki H, Imai T, Ohe-Toyota M, Maruyama R, Nojima M, Sasaki Y, Sekido Y, Hiratsuka H, Shinomura Y, Imai K, Itoh F, Tokino T (2007) PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res 13(16):4786–4794

    Article  PubMed  CAS  Google Scholar 

  78. Ono S, Oue N, Kuniyasu H, Suzuki T, Ito R, Matsusaki K, Ishikawa T, Tahara E, Yasui W (2002) Acetylated histone H4 is reduced in human gastric adenomas and carcinomas. J Exp Clin Cancer Res 21(3):377–382

    PubMed  CAS  Google Scholar 

  79. Mitani Y, Oue N, Hamai Y, Aung PP, Matsumura S, Nakayama H, Kamata N, Yasui W (2005) Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma. J Pathol 205(1):65–73

    Article  PubMed  CAS  Google Scholar 

  80. Xia G, Schneider-Stock R, Diestel A, Habold C, Krueger S, Roessner A, Naumann M, Lendeckel U (2008) Helicobacter pylori regulates p21(WAF1) by histone H4 acetylation. Biochem Biophys Res Commun 369(2):526–531

    Article  PubMed  CAS  Google Scholar 

  81. Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861–874

    Article  PubMed  CAS  Google Scholar 

  82. Tekcham DS, Tiwari PK (2016) Non-coding RNAs as emerging molecular targets in gallbladder cancer. Gene 588(1):79–85

    Article  PubMed  CAS  Google Scholar 

  83. Kang C, Song JJ, Lee J, Kim MY (2014) Epigenetics: an emerging player in gastric cancer. World J Gastroenterol 20(21):6433–6447

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Suzuki H, Maruyama R, Yamamoto E, Kai M (2012) DNA methylation and microRNA dysregulation in cancer. Mol Oncol 6(6):567–578

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  85. Yin H, Song P, Su R, Yang G, Dong L, Luo M, Wang B, Gong B, Liu C, Song W, Wang F, Ma Y, Zhang J, Wang W, Yu J (2016) DNA methylation mediated down-regulating of MicroRNA-33b and its role in gastric cancer. Sci Rep 6:18824. https://doi.org/10.1038/srep18824

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, Yan M, Qu QL, Zhu ZG, Liu BY (2012) microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol Rep 27(6):1960–1966

    PubMed  Google Scholar 

  87. Li P, Chen X, Su L, Li C, Zhi Q, Yu B, Sheng H, Wang J, Feng R, Cai Q, Li J, Yu Y, Yan M, Liu B, Zhu Z (2013) Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One 8(6):e66782. https://doi.org/10.1371/journal.pone.0066782

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  88. Tsai KW, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, Ho MR, Lai CH, Kao HW, Fang WL, Huang KH, Lin WC (2011) Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics 6(10):1189–1197

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X (2011) miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci 56(7):2009–2016

    Article  PubMed  CAS  Google Scholar 

  90. Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, Yu X, Xia T, Cui L, Guo J (2013) MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 518(2):351–359

    Article  PubMed  CAS  Google Scholar 

  91. Wei B, Song Y, Zhang Y, Hu M (2013) microRNA-449a functions as a tumor-suppressor in gastric adenocarcinoma by targeting Bcl-2. Oncol Lett 6(6):1713–1718

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J, Zhou T (2010) MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 20(7):784–793

    Article  PubMed  CAS  Google Scholar 

  93. Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y, Nishida T, Bamba T, Kanda T, Ajioka Y, Taguchi T, Okahara S, Takahashi H, Nishida Y, Hosokawa M, Hasegawa T, Tokino T, Hirata K, Imai K, Toyota M, Shinomura Y (2012) Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res 72(5):1126–1136

    Article  PubMed  CAS  Google Scholar 

  94. Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P, Liu P (2013) Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol 71(5):1159–1171

    Article  PubMed  CAS  Google Scholar 

  95. Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P (2012) miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 69(3):723–731

    Article  PubMed  CAS  Google Scholar 

  96. Eddy SR (2001) Non–coding RNA genes and the modern RNA world. Nat Rev Genet 2(12):919–929

    Article  PubMed  CAS  Google Scholar 

  97. S D, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A et al (2012) Landscape of transcription in human cells. Nature 489(7414):101–108

    Article  CAS  Google Scholar 

  98. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K, Bajic VB, Brenner SE, Batalov S, Forrest AR, Zavolan M, Davis MJ, Wilming LG, Aidinis V, Allen JE, Ambesi-Impiombato A, Apweiler R, Aturaliya RN, Bailey TL, Bansal M, Baxter L, Beisel KW, Bersano T, Bono H, Chalk AM, Chiu KP, Choudhary V, Christoffels A, Clutterbuck DR, Crowe ML, Dalla E, Dalrymple BP, de Bono B, Della Gatta G, di Bernardo D, Down T, Engstrom P, Fagiolini M, Faulkner G, Fletcher CF, Fukushima T, Furuno M, Futaki S, Gariboldi M, Georgii-Hemming P, Gingeras TR, Gojobori T, Green RE, Gustincich S, Harbers M, Hayashi Y, Hensch TK, Hirokawa N, Hill D, Huminiecki L, Iacono M, Ikeo K, Iwama A, Ishikawa T, Jakt M, Kanapin A, Katoh M, Kawasawa Y, Kelso J, Kitamura H, Kitano H, Kollias G, Krishnan SP, Kruger A, Kummerfeld SK, Kurochkin IV, Lareau LF, Lazarevic D, Lipovich L, Liu J, Liuni S, McWilliam S, Madan Babu M, Madera M, Marchionni L, Matsuda H, Matsuzawa S, Miki H, Mignone F, Miyake S, Morris K, Mottagui-Tabar S, Mulder N, Nakano N, Nakauchi H, Ng P, Nilsson R, Nishiguchi S, Nishikawa S, Nori F, Ohara O, Okazaki Y, Orlando V, Pang KC, Pavan WJ, Pavesi G, Pesole G, Petrovsky N, Piazza S, Reed J, Reid JF, Ring BZ, Ringwald M, Rost B, Ruan Y, Salzberg SL, Sandelin A, Schneider C, Schönbach C, Sekiguchi K, Semple CA, Seno S, Sessa L, Sheng Y, Shibata Y, Shimada H, Shimada K, Silva D, Sinclair B, Sperling S, Stupka E, Sugiura K, Sultana R, Takenaka Y, Taki K, Tammoja K, Tan SL, Tang S, Taylor MS, Tegner J, Teichmann SA, Ueda HR, van Nimwegen E, Verardo R, Wei CL, Yagi K, Yamanishi H, Zabarovsky E, Zhu S, Zimmer A, Hide W, Bult C, Grimmond SM, Teasdale RD, Liu ET, Brusic V, Quackenbush J, Wahlestedt C, Mattick JS, Hume DA, Kai C, Sasaki D, Tomaru Y, Fukuda S, Kanamori-Katayama M, Suzuki M, Aoki J, Arakawa T, Iida J, Imamura K, Itoh M, Kato T, Kawaji H, Kawagashira N, Kawashima T, Kojima M, Kondo S, Konno H, Nakano K, Ninomiya N, Nishio T, Okada M, Plessy C, Shibata K, Shiraki T, Suzuki S, Tagami M, Waki K, Watahiki A, Okamura-Oho Y, Suzuki H, Kawai J, Hayashizaki Y, FANTOM Consortium, RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group) (2005) The transcriptional landscape of the mammalian genome. Science 309(5740):1559–1563

    Article  PubMed  CAS  Google Scholar 

  99. Yang Q, Zhang RW, Sui PC, He HT, Ding L (2015) Dysregulation of non-coding RNAs in gastric cancer. World J Gastroenterol 21(39):10956–10981

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T, Fujiwara H, Okamoto K, Otsuji E (2013) Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res 33(8):3185–3193

    PubMed  CAS  Google Scholar 

  101. Zhou X, Yin C, Dang Y, Ye F, Zhang G (2015) Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer. Sci Rep 5:11516. https://doi.org/10.1038/srep11516

    Article  PubMed  PubMed Central  Google Scholar 

  102. Endo H, Shiroki T, Nakagawa T, Yokoyama M, Tamai K, Yamanami H, Fujiya T, Sato I, Yamaguchi K, Tanaka N, Iijima K, Shimosegawa T, Sugamura K, Satoh K (2013) Enhanced expression of long non-coding RNA HOTAIR is associated with the development of gastric cancer. PLoS One 8(10):e77070. https://doi.org/10.1371/journal.pone.0077070.eCollection2013

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Zhao Y, Guo Q, Chen J, Hu J, Wang S, Sun Y (2014) Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep 31(1):358–364

    Article  PubMed  CAS  Google Scholar 

  104. Sun M, Xia R, Jin F, Xu T, Liu Z, De W, Liu X (2014) Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 35(2):1065–1073

    Article  PubMed  CAS  Google Scholar 

  105. Cao WJ, Wu HL, He BS, Zhang YS, Zhang ZY (2013) Analysis of long non-coding RNA expression profiles in gastric cancer. World J Gastroenterol 19(23):3658–3664

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Li CY, Liang GY, Yao WZ, Sui J, Shen X, Zhang YQ, Peng H, Hong WW, Ye YC, Zhang ZY, Zhang WH, Yin LH, Pu YP (2016) Integrated analysis of long non-coding RNA competing interactions reveals the potential role in progression of human gastric cancer. Int J Oncol 48(5):1965–1976

    Article  PubMed  CAS  Google Scholar 

  107. Rich S, Ganz R, Levy PS (1983) Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. Am J Cardiol 52(8):1104–1107

    Article  PubMed  CAS  Google Scholar 

  108. Strolin Benedetti M, Rumigny JF, Dostert P (1984) Mechanisms of action and biochemical toxicology of valproic acid. Encéphale 10(4):177–188

    PubMed  CAS  Google Scholar 

  109. Windle J, Prystowsky EN, Miles WM, Heger JJ (1987) Pharmacokinetic and electrophysiologic interactions of amiodarone and procainamide. Clin Pharmacol Ther 41(6):603–610

    Article  PubMed  CAS  Google Scholar 

  110. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23(17):3948–3956

    Article  PubMed  CAS  Google Scholar 

  111. Kaminskas Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11(10):3604–3608

    Article  PubMed  Google Scholar 

  112. Zambrano P, Segura-Pacheco B, Perez-Cardenas E, Cetina L, Revilla-Vazquez A, Taja-Chayeb L, Chavez-Blanco A, Angeles E, Cabrera G, Sandoval K, Trejo-Becerril C, Chanona-Vilchis J, Duenas-González A (2005) A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 5:44

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Zhang X, Yashiro M, Ren J, Hirakawa K (2006) Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 16(3):563–568

    PubMed  CAS  Google Scholar 

  114. Riester D, Hildmann C, Schwienhorst A (2007) Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Appl Microbio Biotechnol 75(3):499–514

    Article  CAS  Google Scholar 

  115. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T, Imai K (2003) Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63(24):8606–8613

    PubMed  CAS  Google Scholar 

  116. Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S, Miyazaki K (2006) The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol 41(2):133–139

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Institute of Medical Science, Banaras Hindu University, Varanasi, 221005, India

    Puneet, Satendra Tiwari & A. Khanna

  2. Cancer Genetics Laboratory, Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, 221005, India

    Hasan Raza Kazmi, Soni Kumari & Gopeshwar Narayan

Authors
  1. Puneet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hasan Raza Kazmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Soni Kumari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satendra Tiwari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Khanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gopeshwar Narayan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Puneet.

Ethics declarations

Conflicts of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Puneet, Kazmi, H.R., Kumari, S. et al. Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers. Pathol. Oncol. Res. 24, 757–770 (2018). https://doi.org/10.1007/s12253-018-0410-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-018-0410-z

Keywords

Search

Navigation